Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 100

1.

The TLR-2/TLR-6 agonist macrophage-activating lipopeptide-2 augments human NK cell cytotoxicity when PGE2 production by monocytes is inhibited by a COX-2 blocker.

Müller C, Tufa DM, Chatterjee D, Mühlradt PF, Schmidt RE, Jacobs R.

Cancer Immunol Immunother. 2015 Sep;64(9):1175-84. doi: 10.1007/s00262-015-1723-3. Epub 2015 Jun 3.

PMID:
26036909
2.

Peripheral and central cyclooxygenase (COX) products may contribute to the manifestation of brain-controlled sickness responses during localized inflammation induced by macrophage-activating lipopeptide-2 (MALP-2).

Knorr C, Marks D, Gerstberger R, Mühlradt PF, Roth J, Rummel C.

Neurosci Lett. 2010 Jul 26;479(2):107-11. doi: 10.1016/j.neulet.2010.05.036. Epub 2010 May 16.

PMID:
20580659
3.

Toll-like receptor 2/6 stimulation promotes angiogenesis via GM-CSF as a potential strategy for immune defense and tissue regeneration.

Grote K, Schuett H, Salguero G, Grothusen C, Jagielska J, Drexler H, Mühlradt PF, Schieffer B.

Blood. 2010 Mar 25;115(12):2543-52. doi: 10.1182/blood-2009-05-224402. Epub 2010 Jan 7.

4.

Synthetic lipopeptide MALP-2 inhibits intracellular growth of Mycobacterium bovis BCG in alveolar macrophages-preliminary data.

Jörgens G, Bange FC, Mühlradt PF, Pabst R, Maus UA, Tschernig T.

Inflammation. 2009 Aug;32(4):247-51. doi: 10.1007/s10753-009-9127-1.

PMID:
19543820
5.

Intracutaneous injection of the macrophage-activating lipopeptide-2 (MALP-2) which accelerates wound healing in mice--a phase I trial in 12 patients.

Niebuhr M, Mühlradt PF, Wittmann M, Kapp A, Werfel T.

Exp Dermatol. 2008 Dec;17(12):1052-6. doi: 10.1111/j.1600-0625.2008.00750.x.

PMID:
18713273
6.

Intratumoural injection of the toll-like receptor-2/6 agonist 'macrophage-activating lipopeptide-2' in patients with pancreatic carcinoma: a phase I/II trial.

Schmidt J, Welsch T, Jäger D, Mühlradt PF, Büchler MW, Märten A.

Br J Cancer. 2007 Sep 3;97(5):598-604. Epub 2007 Jul 31.

7.

Pyrexia, anorexia, adipsia, and depressed motor activity in rats during systemic inflammation induced by the Toll-like receptors-2 and -6 agonists MALP-2 and FSL-1.

Hübschle T, Mütze J, Mühlradt PF, Korte S, Gerstberger R, Roth J.

Am J Physiol Regul Integr Comp Physiol. 2006 Jan;290(1):R180-7. Epub 2005 Sep 8.

8.

Attenuated pathogenesis of polymicrobial peritonitis in mice after TLR2 agonist pre-treatment involves ST2 up-regulation.

Feterowski C, Novotny A, Kaiser-Moore S, Mühlradt PF, Rossmann-Bloeck T, Rump M, Holzmann B, Weighardt H.

Int Immunol. 2005 Aug;17(8):1035-46. Epub 2005 Jul 6.

PMID:
16000329
9.

Efficacy of macrophage-activating lipopeptide-2 combined with interferon-gamma in a murine asthma model.

Weigt H, Nassenstein C, Tschernig T, Mühlradt PF, Krug N, Braun A.

Am J Respir Crit Care Med. 2005 Sep 1;172(5):566-72. Epub 2005 May 18.

PMID:
15901606
10.

The mucosal adjuvant macrophage-activating lipopeptide-2 directly stimulates B lymphocytes via the TLR2 without the need of accessory cells.

Borsutzky S, Kretschmer K, Becker PD, Mühlradt PF, Kirschning CJ, Weiss S, Guzmán CA.

J Immunol. 2005 May 15;174(10):6308-13.

11.

The macrophage-activating lipopeptide-2 accelerates wound healing in diabetic mice.

Deiters U, Barsig J, Tawil B, Mühlradt PF.

Exp Dermatol. 2004 Dec;13(12):731-9.

PMID:
15560756
12.
13.

Tumour suppression induced by the macrophage activating lipopeptide MALP-2 in an ultrasound guided pancreatic carcinoma mouse model.

Schneider C, Schmidt T, Ziske C, Tiemann K, Lee KM, Uhlinsky V, Behrens P, Sauerbruch T, Schmidt-Wolf IG, Mühlradt PF, Schmidt J, Märten A.

Gut. 2004 Mar;53(3):355-61.

14.

Association of Mycoplasma fermentans with Adamantiades-Behçet's disease.

Zouboulis CC, Turnbull JR, Mühlradt PF.

Adv Exp Med Biol. 2003;528:191-4. No abstract available.

PMID:
12918688
16.

High seroprevalence of anti-Mycoplasma fermentans antibodies in patients with malignant aphthosis.

Zouboulis CC, Turnbull JR, Mühlradt PF.

J Invest Dermatol. 2003 Jul;121(1):211-2. No abstract available.

17.

Efficient mucosal delivery of the HIV-1 Tat protein using the synthetic lipopeptide MALP-2 as adjuvant.

Borsutzky S, Fiorelli V, Ebensen T, Tripiciano A, Rharbaoui F, Scoglio A, Link C, Nappi F, Morr M, Buttó S, Cafaro A, Mühlradt PF, Ensoli B, Guzmán CA.

Eur J Immunol. 2003 Jun;33(6):1548-56.

18.

Synthetic mycoplasma-derived lipopeptide MALP-2 induces maturation and function of dendritic cells.

Weigt H, Mühlradt PF, Emmendörffer A, Krug N, Braun A.

Immunobiology. 2003;207(3):223-33.

PMID:
12777064
19.

Differential recognition of structural details of bacterial lipopeptides by toll-like receptors.

Morr M, Takeuchi O, Akira S, Simon MM, Mühlradt PF.

Eur J Immunol. 2002 Dec;32(12):3337-47.

20.

The Mycoplasma-derived lipopeptide MALP-2 is a potent mucosal adjuvant.

Rharbaoui F, Drabner B, Borsutzky S, Winckler U, Morr M, Ensoli B, Mühlradt PF, Guzmán CA.

Eur J Immunol. 2002 Oct;32(10):2857-65.

21.

In vivo effects of a synthetic 2-kilodalton macrophage-activating lipopeptide of Mycoplasma fermentans after pulmonary application.

Lührmann A, Deiters U, Skokowa J, Hanke M, Gessner JE, Mühlradt PF, Pabst R, Tschernig T.

Infect Immun. 2002 Jul;70(7):3785-92.

22.
23.

Discrimination of bacterial lipoproteins by Toll-like receptor 6.

Takeuchi O, Kawai T, Mühlradt PF, Morr M, Radolf JD, Zychlinsky A, Takeda K, Akira S.

Int Immunol. 2001 Jul;13(7):933-40.

PMID:
11431423
24.

Synergy and cross-tolerance between toll-like receptor (TLR) 2- and TLR4-mediated signaling pathways.

Sato S, Nomura F, Kawai T, Takeuchi O, Mühlradt PF, Takeda K, Akira S.

J Immunol. 2000 Dec 15;165(12):7096-101.

25.
26.

Induction of cytokines and chemokines in human monocytes by Mycoplasma fermentans-derived lipoprotein MALP-2.

Kaufmann A, Mühlradt PF, Gemsa D, Sprenger H.

Infect Immun. 1999 Dec;67(12):6303-8.

27.

Effect of MALP-2, a lipopeptide from Mycoplasma fermentans, on bone resorption in vitro.

Piec G, Mirkovitch J, Palacio S, Mühlradt PF, Felix R.

Infect Immun. 1999 Dec;67(12):6281-5.

30.

Activation of nuclear factor-kappaB in macrophages by mycoplasmal lipopeptides.

Sacht G, Märten A, Deiters U, Süssmuth R, Jung G, Wingender E, Mühlradt PF.

Eur J Immunol. 1998 Dec;28(12):4207-12.

31.

Structure and specific activity of macrophage-stimulating lipopeptides from Mycoplasma hyorhinis.

Mühlradt PF, Kiess M, Meyer H, Süssmuth R, Jung G.

Infect Immun. 1998 Oct;66(10):4804-10.

32.
33.
34.
37.

Identification of the mouse helper T lymphocyte differentiation antigen 3G11 as the ganglioside IV3(NeuAc)2-GgOse4Cer.

Dittrich F, Hayakawa K, Nimtz M, Ebel F, Mühlradt PF.

Biochem Biophys Res Commun. 1994 May 16;200(3):1557-63.

PMID:
8185611
39.
41.

Gangliosides: differentiation markers for murine T helper lymphocyte subpopulations TH1 and TH2.

Ebel F, Schmitt E, Peter-Katalinić J, Kniep B, Mühlradt PF.

Biochemistry. 1992 Dec 8;31(48):12190-7.

PMID:
1457415
42.

Role of IL-6, IL-2, and IL-4 in the in vitro induction of cytotoxic T cells.

Quentmeier H, Klaucke J, Mühlradt PF, Drexler HG.

J Immunol. 1992 Nov 15;149(10):3316-20.

PMID:
1431108
43.

Tetrazolium [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] reduction by mycoplasmas.

Kirchhoff H, Maass C, Runge M, Franz B, Schmidt R, Quentmeier H, Mühlradt PF.

Int J Syst Bacteriol. 1992 Jul;42(3):506-8.

PMID:
1503978
46.

Immunochemical detection of glycosphingolipids on thin-layer chromatograms.

Kniep B, Mühlradt PF.

Anal Biochem. 1990 Jul;188(1):5-8.

PMID:
1699450
47.

Modulation of Forssman glycosphingolipid expression by murine macrophages: coinduction with class II MHC antigen by the lymphokines IL4 and IL6.

von Kleist R, Schmitt E, Westermann J, Mühlradt PF.

Immunobiology. 1990 Jun;180(4-5):405-18.

PMID:
2168860
48.
49.

Monoclonal antibodies against the human lymphocyte differentiation antigen CD 76 bind to gangliosides.

Kniep B, Mühlradt PF, Dörken B, Moldenhauer G, Vilella R, Schwartz-Albiez R.

FEBS Lett. 1990 Feb 26;261(2):347-9.

Supplemental Content

Loading ...
Support Center